ID   1259-mel
AC   CVCL_GR81
SY   1259-MEL; 1259mel; 1259MEL
DR   Cosmic; 2759882
DR   TOKU-E; 4040
DR   Wikidata; Q54581206
RX   PubMed=8537970;
RX   PubMed=15661905;
CC   From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   Sequence variation: B2M p.Leu15Phefs*41 (c.43_44delCT) (PubMed=15661905).
CC   Derived from metastatic site: Subcutaneous.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 29-10-20; Version: 5
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=15661905; DOI=10.4049/jimmunol.174.3.1462;
RA   Chang C.-C., Campoli M., Restifo N.P., Wang X., Ferrone S.;
RT   "Immune selection of hot-spot beta 2-microglobulin gene mutations,
RT   HLA-A2 allospecificity loss, and antigen-processing machinery
RT   component down-regulation in melanoma cells derived from recurrent
RT   metastases following immunotherapy.";
RL   J. Immunol. 174:1462-1471(2005).
//